BioAtla(US:BCAB) Globenewswireยท2025-07-17 12:00Core Insights - BioAtla, Inc. is a clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors [1][3] - The company will present a first-in-human phase I study of a dual-CAB EpCAM x CD3 bispecific T-cell engager (TCE), BA3182, targeting treatment refractory metastatic adenocarcinoma at the 2025 ESMO TAT Asia Meeting [2] Company Overview - BioAtla operates in San Diego, California, and has a presence in Beijing, China through a partnership with BioDuro-Sundia for preclinical development services [3] - The company utilizes its proprietary CAB platform technology to develop novel monoclonal and bispecific antibodies, aiming for selective targeting, greater efficacy, lower toxicity, and cost-efficient manufacturing compared to traditional antibodies [3] - BioAtla holds extensive patent coverage with over 780 active patent matters, including more than 500 issued patents, covering methods of making, screening, and manufacturing CAB product candidates [3]